Jun 5 2012
The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA (Abstract #4034).
Trabedersen, is an antisense compound that specifically inhibits expression of transforming growth factor beta 2 (TGF-β2) – a protein which is overexpressed in advanced tumors and which triggers key cancer pathomechanisms, i.e. suppression of antitumor immune response and metastasis.
"Trabedersen shows excellent safety and encouraging survival results in patients with advanced solid tumors", concludes Dr. Hubert Heinrichs, Chief Medical Officer at Antisense Pharma. "In comparison to current treatments for late stage pancreatic carcinoma or malignant melanoma, our compound may prove to be a very novel and attractive therapeutic alternative."
Advances in bladder cancer treatments offer hope for curative care